Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

NCT06015568 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

Interventions

DRUG: MCLA-129: 1500mg or 2000mg IV Q2W
DRUG: Befotertinib: 75 mg or 100 mg Po QD

Sponsor

Betta Pharmaceuticals Co., Ltd.